MEME KANSERİNDE UZUN SÜRELİ TAMOKSİFEN KULLANIMININ KADIN AŞAĞI GENİTAL TRAKTUS ÜZERİNE ETKİSİ

Abstract

Sentetik anti-östrojenik bir ilaç olan Tamoksifen (TAM) meme kanseri tedavisinde yaygın olarak kullanılmaktadır. Uzun süreli TAM kullanımı parsiyel agonistik etkisine bağlı olarak pre-malign ve malign uterin korpus lezyonları ve fonksiyonel ovaryen kistlere yol açabilir. Bununla birlikte, meme kanseri öyküsü olan hastalarda TAM kullanımı ile aşağı kadın genital sistemi lezyonları, örneğin servikal polip ve servikal intra-epitelyal neoplazi (CIN), arasındaki ilişki hakkında literatürde çok az veri vardır. Mevcut ‘review’ bu konu hakkında güncel bir derleme sunmaktadır.

Keywords

• Tamoksifen, Meme kanseri, Kadın aşağı genital sistemi

References

1. 1. Ugwumadu AH, Carmichael PL, Neven P. Tamoxifen and the female genital tract. Int J Gynecol Cancer 1998; 8: 6-15.
2. 2. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P- 1 Study. J Natl Cancer Inst 1998; 90 : 1371-1388.
3. 3. Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG committee opinion: Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 2001; 73: 77-79 .
4. 4. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-2054.
5. 5. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000; 22: 1-11.
6. 6. Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004; 30: 291-301.
7. 7. Neven P, Vergote I. Tamoxifen, screening and new oestrogen receptor modulators. Best Pract Res Clin Obstet Gynaecol 2001; 15: 365-380.
8. 8. Lhomme C, Pautier P, Zagame L, et al. Endometrial surveillance of women on tamoxifen. Gynecol Obstet Fertil 2003; 31: 647-656. 9. Cohen I. Benign gynecologic conditions in tamoxifen

9. treated patients. Am J Obstet Gynecol 2006; 194: 1204- 1205 .
10. 10. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984; 44: 112-119.
11. 11. Le Donne M, Lentini M, De Meo L, Benedetto V, Mesiti M. Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynaecol Oncol 2005; 26: 623-626.
12. 12. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer 2005; 15: 1239-1242.
13. 13. Inal MM, Incebiyik A, Sanci M, Yildirim Y, Polat M, Pilanci B, et al. Ovarian cysts in tamoxifen-treated women with breast cancer. Eur J Obstet Gynecol Reprod Biol 2005; 120: 104-106.
14. 14. Gill BL, Simpson JF, Somlo G, McGonigle KF, Wilczynski SP. Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. Diagn Cytopathol 1998; 19: 417-422.
15. 15. Varras M, Polyzos D, Akrivis CH. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003; 24: 258-268.
16. 16. Nucci MR, Young RH, Fletcher CDM. Cellular pseudosarcomatous fibroepithelial stromal polyps of the lower female genital tract: an unrecognized lesion often misdiagnosed as sarcoma. Am J Surg Pathol 2000; 24: 231-240.
17. 17. Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N, Karydas I, Stravolemos K. Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Resb 1998; 18: 625- 629.
18. 18. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. BMJ 1977; 1: 1351-1352.
19. 19. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996; 65: 1083-1089.
20. 20. Yang YJ, Trapkin LK, Demoski RK, Bellerdine J, Powers CN. The small blue cell dilemma associated with tamoxifen therapy. Arch Pathol Lab Med 2001; 125: 1047-1050.
21. 21. Friedrich M, Mink D, Villena-Heinsen C, Woll Hermann A, Schmidt W. Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol 1998; 80: 221-225.
22. 22. Yokosuka K, Teshima H, Katase K, Fujimoto I, Yamauchi K, Hasumi K, et al. Effects of long-term administration of tamoxifen on vaginal epithelium and complications of endometrial lesions in breast cancer patients. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47: 125-132.
23. 23. Fornander T, Rutqvist LE, Wilking N. Effects of tamoxifen on the female genital tract. Ann NYAcad Sci 1991; 622: 469-476.
24. 24. Opjorden SL, Caudill JL, Humphrey SK, Salomao DR. Small cells in cervical vaginal smears of patients treated with tamoxifen. Cancer 2001; 93: 23-28.
25. 25. Silfen SL, Ciaccia AV, Bryant HU. Selective estrogen receptor modulators: tissue specificity and differential uterine effects. Climacteric 1999; 2: 268-283.
26. 26. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005; 192: 1230- 1237.
27. 27. Ganesan R, McCluggage WG, Hirschowitz L, Rollason TP. Superficial myofibroblastoma of the lower female genital tract: report of a series including tumours with a vulva location. Histopathology 2005; 46: 137-143.
28. 28. Varras M, Akrivis C, Demou A, Kitsiou E, Antoniou N. Angiomyofibroblastoma of the vagina in a postmenopausal breast cancer patient treated with tamoxifen: clinicopathologic analysis of a case and review of the literature. Int J Gynecol Cancer 2006; 16: 581-585.
29. 29. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97: 855-866.
30. 30. Marttunen MB, Cacciatore B, Hietanen P, Pyrhönen S, Tiitinen A, Wahlström T, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001; 84: 897-902
31. 31. Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, et al. Acute effects of tamoxifen and third generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004; 15: 753-760.
32. 32. Mourits MJ, Bockermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, et al. Tamoxifen effects on subjective and psychosexual wellbeing in a randomized breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002; 86: 1546-1550.
33. 33. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999; 17: 1488-1492.
34. 34. Park K, Ahn K, Lee S, Ryu S, Park Y, Azadzoi KM. Decreased circulating levels of estrogen alter vaginal and clitoral blood flow and structure in the rabbit. Int J Impot Res 2001; 13: 116-124.
35. 35. Min K, Munarriz R, Kim NN, Goldstein I, Traish A. Effects of ovariectomy and estrogen and androgen treatment on sildenafil mediated changes in female genital blood flow and vaginal lubrication in the animal model. Am J Obstet Gynecol 2002; 187: 1370-1376.
36. 36. Min K, Munarriz R, Kim NN, Choi S, O’Connell L, Goldstein I, et al. Effects of ovariectomy and estrogen replacement on basal and pelvic nerve stimulated vaginal lubrication in an animal model. J Sex Marital Ther 2003; 29: 77-84.
37. 37. Kim SW, Kim NN, Jeong SJ, Munarriz R, Goldstein I, Traish AM. Modulation of rat vaginal blood flow and estrogen receptor by estradiol. J Urol 2004; 172: 1538- 1543.
38. 38. Li H, Meininger CJ, Kelly KA, Hawker JR, Morris SM, Wu G. Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol 2002; 282: 64-69.
39. 39. Morris SM Jr. Recent advances in arginine metabolism. Curr Opin Clin Nutr Metab Care 2004; 7: 45-51.
40. 40. Raz S, Caine M, Zeigler M. The vascular component in the production of intraurethral pressure. J Urol 1972; 108: 93-96.
41. 41. Rud T, Andersson KE, Asmussen M, Hunting A, Ulmsten U. Factors maintaining the intraurethral pressure in women. Invest Urol 1980; 17: 343-347.
42. 42. Faria CA, Sartori MG, Baracat EC, de Lima GR, Girao MJ. Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 56-59.
43. 43. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 2005; 8: 214-220.
44. 44. Rekers H, Drogendijk AC, Valkenburg HA, Riphagen F. The menopause, urinary incontinence and other symptoms of the genito-urinary tract. Maturitas 1992; 15: 101-111.
45. 45. Grodstein F, Lifford K, Resnick NM, Curhan GC. Post menopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004; 103: 254- 260.
46. 46. Vardy MD, Lindsay R, Scotti RJ, Mikhail M, Richart RM, Nieves J, et al. Short term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003; 189: 81-88.
47. 47. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94: 39-49.